CRC Research Update — September 06, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Sunday, September 06, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
SCREENING
American Cancer Society adds blood-based tests to CRC screening guidelinesIn May 2026, the American Cancer Society updated their recommendations to include blood-based tests for individuals who decline or do not complete preferred screening tests, with a colonoscopy within 6 months required for positive results. (Lancet Gastroenterology & Hepatology)
-
RESEARCH
Real-world data on HER2-positive metastatic CRC from 14 Japanese centersA multicenter retrospective study of 45 patients with HER2-positive metastatic colorectal cancer diagnosed between 2010 and 2023 examined outcomes with different first-line targeted agents and assessed safety of trastuzumab plus pertuzumab. (International Journal of Clinical Oncology)
-
LIVING WITH CRC
Smartphone-based education program for family caregivers of CRC patientsA randomized controlled trial of 80 family caregivers of CRC patients tested a smartphone-based educational program designed to meet supportive care needs compared to routine care, with assessments completed before and 4 weeks after the intervention. (Supportive Care in Cancer)
-
LIVING WITH CRC
Pre-chemotherapy anxiety and sleep disturbance linked to immune changes and quality of lifeA prospective study of 268 CRC patients assessed within 24 hours before their first chemotherapy cycle found that anxiety-sleep disturbance symptoms were associated with neuroendocrine dysregulation, cellular immune alterations, and quality of life, with cortisol and IL-6 acting as biological mediators. (Neuroimmunomodulation)
Research continues to expand screening options and support for patients and caregivers navigating CRC.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data